Lundbeck公司首席执行官和总裁黛博拉它是一家t Dunsire会谈o Jo Shorthouse about what drew her to the pharma company, which specializes in neurological disorders. She discusses the recent setback in the Phase III trial of AF35700, its novel antipsychotic in treatment resistant schizophrenia, and how the company is going to take the product forward. She also shares her thoughts on R&D in CNS, what lessons the industry has learned to date, and how it will move forward for better therapies.